Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity accelerates DM1 Phase III trial on the heels of further positive data
Avidity Biosciences Announces Positive AOC 1001 Long-term Data
Avidity Biosciences Honors Rare Disease Day®
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044
SAN DIEGO, Feb. 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension (MARINA-OLE™) trial in people living with myotonic dystrophy type 1 (DM1) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.